Showing 1,001 - 1,020 results of 100,196 for search '(( end point decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.14s Refine Results
  1. 1001
  2. 1002
  3. 1003
  4. 1004
  5. 1005
  6. 1006
  7. 1007
  8. 1008
  9. 1009
  10. 1010
  11. 1011
  12. 1012
  13. 1013
  14. 1014
  15. 1015
  16. 1016

    Increased oxidative stress, viral load and decreased survivability of N2a following RIG-I ablation. by Arshed Nazmi (215284)

    Published 2011
    “…The mean fluorescence intensities obtained from each group are depicted in the figure. (1-Unstained, 2-Mock-infected; 3-JEV-infected, 4-JEV+Sc-MO, 5-JEV+rMO) (A). Immunoblot analysis to detect JEV NS-5 expression also showed enhancement in JEV+rMO when compared to either JEV-infected or JEV+ScMO groups (B&C). …”
  17. 1017
  18. 1018

    Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial by Piero Ruscitti (3684799)

    Published 2019
    “…Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab), and the primary end point was the change in percentage of glycated haemoglobin (HbA1c%) (EudraCT: 2012-005370-62 ClinicalTrial.gov: NCT02236481).…”
  19. 1019
  20. 1020

    mFIZZ1′ and mFIZZ1 decreased the IL-13 and IL-5 secretion of splenocytes. by Wael Gad (285901)

    Published 2013
    “…Recombinant mFIZZ1′ and mFIZZ1 expressed with or without hQSOX1b were used at 200 ng/ml. rRa is the bacterial recombinant FIZZ1 (200 ng/ml) from (Peprotech) and PBS is the control. (<b>A</b>) Recombinant mFIZZ1′ and mFIZZ1 co-expressed with hQSOX1b significantly decreased the IL-5 secretion compared to the proteins expressed alone. …”